(AGENPARL) - Roma, 23 Febbraio 2023 - (AGENPARL) – gio 23 febbraio 2023 Update from GOV.?UK for: News and communications MHRA safety review of medicines containing pseudoephedrine Page summary: The MHRA is reviewing the evidence relating to the very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversibl…
[Go to the GOV.UK homepage](https://www.gov.uk)
GOV.UK
Update from GOV.?UK for:
News and communications
—————————————————————
[MHRA safety review of medicines containing pseudoephedrine](https://www.gov.uk/government/news/mhra-safety-review-of-medicines-containing-pseudoephedrine?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=3c25802f-1a8f-4652-bfbe-57ddc9bca331&utm_content=immediately)
Page summary:
The MHRA is reviewing the evidence relating to the very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with medicines containing pseudoephedrine
Change made:
First published.
Time updated:
9:10pm, 23 February 2023
—————————————————————